Iodination conditions of KH901, a tumor-specific oncolytic recombinant adenovirus, and its 125I-labeled compounds biodistribution in animals.
- Author:
Yanxia MI
1
;
Yunchun LI
;
Yahong LONG
;
Peng XIE
Author Information
1. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- MeSH:
Adenoviridae;
genetics;
physiology;
Animals;
DNA, Recombinant;
genetics;
Female;
Genetic Vectors;
genetics;
Iodine Radioisotopes;
pharmacokinetics;
Male;
Mice;
Mice, Inbred BALB C;
Oncolytic Viruses;
genetics;
physiology
- From:
Journal of Biomedical Engineering
2009;26(5):1064-1093
- CountryChina
- Language:Chinese
-
Abstract:
In this research was developed high efficiency method using 125I for directly labeling KH901, a tumor-specific oncolytic recombinant adenovirus, biodistribution of 125I-labeled compound in normal mice was investigated. 125I-KH901 was prepared by N-bromosuccinimide labeling method to find the optimal ratio of labeling response. The compounds were isolated and purified by Sephadex-G10 agarose and the radiochemical purity of compounds was analyzed by paper chromatography. The radioactivity biodistribution in mice was measured at different times after caudal vein injection with 0.1ml 125I-KH901. The labeling yield of 125I-KH901 was 78% and the radiochemical purity was 95% after purification by Sephadex-G10 agarose. Biodistribution revealed that the uptake of 125I-KH901 in liver was higher than in other organs at all time points of the experiment. 125I-KH901 was mainly concentrated in liver, kidneys, spleen and lung. It can be seen that N-bromosuccinimide labeling method is an optimal method with simple steps and high labeling yield in labeling KH901 with 125I. 125I-KH901 has a biodistribution trait which is an advantage to treating liver tumors.
